An 81-year-old male with unresectable hepatocellular carcinoma underwent transarterial chemoembolization(TACE)combined with sorafenib.Platelet count was normal before and after TACE treatment,after which oral administration of sorafenib(400 mg po bid)was initiated.During this period,the patient experienced significant diarrhea,so the dosage was reduced to 200 mg po bid.Later,the patient showed obvious gingival bleeding with progressive exacerbation,and his blood routine examination showed a platelet count of 2×109 cells/L.The patient was clinically diagnosed with extreme severe thrombocytopenia.The patient was advised to stop taking sorafenib and was immediately treated with hemostasis,platelet transfusion,and suspended red blood cells.After the above treatment,the patient’s symptoms improved,and he was discharged.Up to the date of follow-up,there was no further bleeding.
展开▼
